Department of Internal Medicine (M.C.A.), Pennsylvania Hospital of the University of Pennsylvania, Pennsylvania, USA.
Duke University School of Medicine (O.O.), Durham, North Carolina, USA.
J Pain Symptom Manage. 2022 Dec;64(6):537-545. doi: 10.1016/j.jpainsymman.2022.08.021. Epub 2022 Sep 2.
Lack of access to supportive care (SC) among cancer patients have been well documented. However, the role of affordability in this disparity among ovarian cancer (OC) patients remain poorly understood.
Patients with OC between 2008 and 2015 were identified from the SEER-Medicare dataset. Racial disparities in utilization of SC medications within the six months of OC diagnosis among patients with Medicare Part D coverage was examined. Multivariable log-binomial regression models were used to examine the associations of race, affordability and SC medications after adjusting for clinical covariates among all patients and separately among patients with advanced-stage disease.
The study cohort included 3697 patients: 86% non-Hispanic White (NHW), 6% non-Hispanic Black (NHB), and 8% Hispanic. In adjusted models, NHB and Hispanic patients were less likely to receive antidepressants compared to NHW patients (NHB: aOR 0.46; 95% CI 0.33-0.63 and Hispanic: aOR 0.79; 95% CI 0.63-0.99). This association persisted for NHB patients with advanced-stage disease (aOR 0.42; 95% CI 0.28-0.62). Patients dual enrolled in Medicaid were more likely to receive antidepressants (overall: aOR 1.34; 95% CI 1.17-1.53 and advanced-stage: aOR 1.29; 95% CI 1.10-1.52). However, patients residing in areas with higher vs. lower proportions of lower educated adults (overall: aOR 0.82; 95% CI 0.70-0.97 and advanced-stage: aOR 0.82; 95% CI 0.68-0.99) were less likely to receive antidepressants.
Black OC patients and those living in lower educated areas were less likely to receive antidepressants as SC. Given the importance of post-primary treatment quality of life for cancer patients, interventions are needed to enhance equitable access to SC.
癌症患者获得支持性护理(SC)的机会不足已得到充分证实。然而,在卵巢癌(OC)患者中,经济负担能力在这种差异中的作用仍知之甚少。
从 SEER-Medicare 数据库中确定了 2008 年至 2015 年间患有 OC 的患者。在有 Medicare Part D 覆盖的患者中,在 OC 诊断后六个月内,检查 SC 药物使用方面的种族差异。使用多变量对数二项式回归模型,在校正所有患者和晚期疾病患者的临床协变量后,检查种族、负担能力和 SC 药物之间的关联。
研究队列包括 3697 名患者:86%为非西班牙裔白人(NHW),6%为非西班牙裔黑人(NHB),8%为西班牙裔。在调整后的模型中,与 NHW 患者相比,NHB 和西班牙裔患者接受抗抑郁药的可能性较小(NHB:aOR 0.46;95%CI 0.33-0.63 和 Hispanic:aOR 0.79;95%CI 0.63-0.99)。这种关联在晚期疾病的 NHB 患者中仍然存在(aOR 0.42;95%CI 0.28-0.62)。同时参加医疗补助和 Medicaid 的患者更有可能接受抗抑郁药(整体:aOR 1.34;95%CI 1.17-1.53 和晚期疾病:aOR 1.29;95%CI 1.10-1.52)。然而,与教育程度较低的成年人比例较高的地区相比,居住在教育程度较低的成年人比例较低的地区的患者(整体:aOR 0.82;95%CI 0.70-0.97 和晚期疾病:aOR 0.82;95%CI 0.68-0.99)接受抗抑郁药的可能性较小。
黑人 OC 患者和居住在教育程度较低地区的患者作为 SC 接受抗抑郁药的可能性较小。鉴于癌症患者初级治疗后生活质量的重要性,需要采取干预措施,以增强 SC 的公平获取。